Formyl peptide receptor 2 and heart disease. (January 2022)

• Record Type: Journal Article
• Authors: Lupisella, John A.; Shirude, Pravin S.; Wurtz, Nicholas R.; Garcia, Ricardo A.
• Is Part Of: Seminars in immunology. Volume 59(2022)
• Publication Date: 2022-01
• Subjects: ANX-A1 Annexin-A1 -- CCR2 CC chemokine receptor 2 -- DAMP Damage associated molecular pattern -- FPR Formyl peptide receptor -- HF Heart failure -- LXA4 Lipoxin A4 -- LV Left ventricular -- MI Myocardial Infarction -- NOS Nitric oxide synthase -- RvD1 Resolvin D1 -- SAA Serum amyloid A; FPR2, Formyl peptide receptor 2 -- Resolution -- MI, Myocardial infarction -- HF, Heart failure; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Immunity -- Periodicals; Immunologie -- Périodiques; Electronic journals; 616.079
• DOI: 10.1016/j.smim.2022.101602
• Languages: English
• ISSNs: 1044-5323

Abstract

Abstract: Formyl peptide receptor type 2 (FPR2) regulates the initiation and resolution phases of the inflammatory response. In the setting of heart injury and disease, dysregulated inflammation can potentiate maladaptive healing and pathological remodeling of the heart leading to cardiac dysfunction and failure. The potential to regulate and resolve adverse inflammation is postulated to improve outcome in the setting of heart disease. This review covers emerging concepts on the role of FPR2 in heart disease and strategies to activate pro-resolution processes to limit disease progression. We summarize key preclinical studies that support use of FPR2 agonists in heart disease. Finally, we briefly discuss the status of FPR2 agonists under evaluation in the clinic.